ArticleInfection and drug resistance2018
Prevalence of multidrug-resistant Gram-negative pathogens isolated from febrile neutropenic cancer patients with bloodstream infections in Egypt and new synergistic antibiotic combinations.
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Review and analysis of the overlapping threats of carbapenem and polymyxin resistant E. coli and Klebsiella in Africa.Antimicrobial resistance and infection control · 2023Pooled it
- Antimicrobial resistance among GLASS pathogens in conflict and non-conflict affected settings in the Middle East: a systematic review.BMC infectious diseases · 2020Pooled it
- Trial
- Article
- Bacterial profile, antimicrobial resistance patterns and associated factors among cancer patients at Hawassa University Comprehensive Specialized Hospital, Sidama region, Southern Ethiopia.BMC infectious diseases · 2026Article
- Burden of extended-spectrum beta-lactamase-producing Enterobacteriaceae among cancer patients in Africa: a systematic review and meta-analysis.Access microbiology · 2026Article
- Clinical Features of Multidrug-Resistant Gram-Negative Bacteremia: A Comparative Study of Cancer and Non-Cancer Patients.Microorganisms · 2025Article
- Prevalence of colistin resistance in multidrug-resistantJAC-antimicrobial resistance · 2025Review
- Carbapenem-Resistant Enterobacteriaceae (CRE) in Children with Cancer: The Impact of Rapid Diagnostics and Targeted Colonization Strategies on Improving Outcomes.Microorganisms · 2025Article
- Monitoring of Antibiotic Resistance Patterns Within Al-Karak Governmental Hospital, Jordan, in 2022.Antibiotics (Basel, Switzerland) · 2024Article
- Deciphering the Intricate Interplay in the Framework of Antibiotic-Drug Interactions: A Narrative Review.Antibiotics (Basel, Switzerland) · 2024Review
- Prevalence and characterization of quinolone resistance and integrons in clinical Gram-negative isolates from Gaza strip, Palestine.Molecular biology reports · 2024Article
- CTX-M, TEM, and SHV Genes inInfection and drug resistance · 2024Article
- Increased rate of multidrug-resistant gram-negative bacterial infections in hospitalized immunocompromised pediatric patients.Frontiers in cellular and infection microbiology · 2024Observational
- Prevalence of blood stream infections and associated factors among febrile neutropenic cancer patients on chemotherapy at Ocean Road Cancer Institute, Tanzania.Infectious agents and cancer · 2023Article
- Prevalence of Multidrug-Resistant Bacteria in Healthcare-Associated Bloodstream Infections at Hospitals in Riyadh, Saudi Arabia.Pathogens (Basel, Switzerland) · 2023Article
- Detection of Extended-spectrum β-lactamase-producing Escherichia coli isolates by isothermal amplification and association of their virulence genes and phylogroups with extraintestinal infection.Scientific reports · 2023Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBloodstream infections with multidrug-resistant (MDR) Gram-negative bacteria (GNB) are among the most frequent complications in immunocompromised cancer patients because of their considerable morbidity and mortality. Several guidelines on antimicrobial therapy have addressed empirical treatment for such serious infections; however, the emergence of microbial resistance has become a significant problem worldwide. MATERIALS AND
methodsIn this study, starting from November 2015 to October 2016, a total of 529 blood specimens were collected from febrile neutropenic cancer patients at a tertiary care cancer hospital in Egypt.
resultsOn examination for positive bacterial growth, it was found that 334 specimens showed no growth, while 195 were positive. Out of the 195 positive culture specimens, 102 (102/195, 52.3%) were Gram-negative and 93 (93/195, 47.7%) were Gram-positive. Out of the 102 GNB, 70 (70/102, 68.6%) were MDR, including
conclusionAccordingly, new empirical antibiotics should be administered including the use of colistin or meropenem alone or both against the MDR GNB in neutropenic cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.